Lyell Immunopharma, Inc. (LYEL)
9.17
-0.09
(-0.97%)
USD |
NASDAQ |
Oct 05, 09:33
Lyell Immunopharma EPS Diluted (Quarterly) : -1.916 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.916 |
| March 31, 2026 | -1.104 |
| December 31, 2025 | -6.622 |
| September 30, 2025 | -2.126 |
| June 30, 2025 | -2.885 |
| March 31, 2025 | -0.1769 |
| December 31, 2024 | -14.40 |
| September 30, 2024 | -0.1739 |
| June 30, 2024 | -0.1794 |
| March 31, 2024 | -0.2386 |
| December 31, 2023 | -0.2091 |
| September 30, 2023 | -0.2024 |
| June 30, 2023 | -0.2554 |
| Date | Value |
|---|---|
| March 31, 2023 | -0.2683 |
| December 31, 2022 | -0.0336 |
| September 30, 2022 | -0.2829 |
| June 30, 2022 | -0.1475 |
| March 31, 2022 | -0.2791 |
| December 31, 2021 | -0.3448 |
| September 30, 2021 | -0.2038 |
| June 30, 2021 | -0.2624 |
| March 31, 2021 | -0.2232 |
| December 31, 2020 | -3.152 |
| September 30, 2020 | -0.149 |
| June 30, 2020 | -0.422 |
| March 31, 2020 | -0.1331 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -1.355 |
| Oncolytics Biotech, Inc. | -0.0788 |
| Sangamo Therapeutics, Inc. | -0.0796 |
| Sarepta Therapeutics, Inc. | -0.0464 |
| Anixa Biosciences, Inc. | -0.0762 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -44.76M |
| Revenue (Quarterly) | 0.004M |
| Total Expenses (Quarterly) | 44.76M |
| Enterprise Value | 59.15M |
| Gross Profit Margin (Quarterly) | -55.45K% |
| Profit Margin (Quarterly) | -1.12M% |
| Earnings Yield | -128.3% |
| Normalized Earnings Yield | -107.03 |